Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases, has entered into a binding term sheet with Actavis Laboratories, FL, Inc. et al. (collectively, "Actavis", now a subsidiary of Teva Pharmaceuticals Industries, Ltd.) involving the ongoing patent litigation regarding Actavis' Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR (extended-release topiramate) capsules.  The binding term sheet permits Actavis to begin selling a generic version of Trokendi XR on January 1, 2023, or earlier under certain circumstances.  The binding term sheet will be submitted to the applicable governmental agencies.

Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR.  Patent protection for Trokendi XR expires no earlier than 2027.

Supernus is represented by attorneys from Haug Partners LLP and its corporate counsel, Saul Ewing LLP.